QVT Financial LP reported ROIVANT SCIENCES LTD (ROIV) in 17 quarterly 13F filings from 2023 Q4 through 2025 Q4. Peak portfolio weight reached 71.6% in 2023 Q4. The latest visible filing shows ROIV at 49.10% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was QVT Financial LP's position in ROIVANT SCIENCES LTD, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
ROIV was reported at 49.10% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
As of 2026 Q1 β sorted by position size
These are the practical questions this page is built to answer before you even open the full history table.
QVT Financial LP reported ROIV across 9 quarterly 13F filings, from 2023 Q4 through 2025 Q4.
The largest reported portfolio weight for ROIV was 71.60% in 2023 Q4.
The most recent filing on this page is 2025 Q4, when QVT Financial LP reported 26,387,021 shares, equal to 49.10% of portfolio, with an estimated market value of $572.6M.
The chart compares QVT Financial LP's quarterly ROIV portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.